Ocular Cicatricial Pemphigoid
Ocular cicatricial pemphigoid (OCP) is a chronic autoimmune blistering disorder that predominantly impacts the mucous membranes of the eyes. At our esteemed company, we are fully committed to driving forward the development solutions of groundbreaking drugs and therapies for OCP.
Overview of Ocular Cicatricial Pemphigoid
Ocular cicatricial pemphigoid (OCP), also known as mucous membrane pemphigoid, is a rare autoimmune disorder that primarily affects the conjunctiva, but can also involve other mucous membranes such as the oral cavity, nasal cavity, and genitalia. The exact cause of OCP is not fully understood, but it is believed to result from an abnormal immune response targeting the basement membrane zone of the affected tissues. This immune response leads to the production of autoantibodies, primarily against components of hemidesmosomes, resulting in inflammation and scarring.
Fig.1 Analysis of conjunctival biopsy samples from cases of ocular cicatricial pemphigoid. (Çiftçi M. D., et al., 2023)
Therapy Discovery and Development for Ocular Cicatricial Pemphigoid
Lubrication of the ocular surface with preservative-free artificial tears, lubricating ointments, and silicone punctal plugs helps alleviate dryness and improve ocular comfort. Additionally, the use of topical immunomodulators, such as cyclosporine-A and tacrolimus, can help control local inflammation and prevent further tissue damage. Moreover, biologic therapies, including anti-TNF agents (etanercept, infliximab), IL-2 antagonist (daclizumab), and the anti-CD20 antibody (rituximab), have shown promise in the management of refractory ocular cicatricial pemphigoid (OCP).
In our esteemed company, we proudly lead the way in the development of groundbreaking drugs and therapies for ocular cicatricial pemphigoid (OCP). To delve deeper into the wealth of knowledge surrounding our exceptional therapy development services for OCP, we invite you to click on the links provided below.
Our Services
Equipped with a highly skilled technical team, our company is dedicated to delivering comprehensive diagnostics and therapy development services for ocular cicatricial pemphigoid (OCP). Furthermore, we specialize in the creation of animal models that faithfully replicate the pathogenesis of OCP. These models serve as invaluable tools for evaluating the effectiveness of potential drug candidates. Additionally, we employ cutting-edge in vitro models to investigate the intricate cellular and molecular mechanisms implicated in OCP.
Spontaneous Animal Models
Our company has expertise in working with spontaneous ocular cicatricial pemphigoid (OCP) animal models, such as dogs and mice, which develop ocular lesions resembling those seen in human patients.
Induced Animal Models
We have developed expertise in inducing OCP in animal models using different approaches, such as immunization with specific antigens or the transfer of autoantibodies. These models enable us to study the immune response and evaluate the efficacy of potential drugs.
The cell-based models we offer, such as fibroblasts, epithelial cells, and immune cells, enable manipulation and study of individual cell types in isolation or in co-culture for validation of potential therapeutics.
We have developed expertise in organoid model development services for OCP. By utilizing patient-derived cells or genetically modified cell lines, we can generate organoids that recapitulate the characteristics of OCP-affected tissues, such as the conjunctiva.
Result Deliver
Our company offers a wide range of preclinical research services aimed at advancing the understanding and therapy development of OCP. In addition to the extensive array of services and models mentioned earlier, our proficiency extends to tailoring personalized solutions and creating disease models that precisely cater to your specific requirements. We take pride in our ability to adapt and customize our offerings to meet your unique needs. If our comprehensive range of services has captured your attention, we sincerely welcome you to reach out to us without any hesitation.
Reference
- Çiftçi M. D., et al. "Clinical approach to ocular cicatricial pemphigoid." Turkish journal of ophthalmology 53.2 (2023): 79.